You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
McKinsey
Mallinckrodt
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Mavrilimumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Mavrilimumab?

Mavrilimumab is an investigational drug.

There have been 8 clinical trials for Mavrilimumab. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2020.

The most common disease conditions in clinical trials are Pneumonia, Respiratory Insufficiency, and Inflammation. The leading clinical trial sponsors are Kiniksa Pharmaceuticals, Ltd., Virginia Commonwealth University, and MedImmune LLC.

There are five US patents protecting this investigational drug and sixty-eight international patents.

Recent Clinical Trials for Mavrilimumab
TitleSponsorPhase
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationKiniksa Pharmaceuticals, Ltd.Phase 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationVirginia Commonwealth UniversityPhase 2
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationKiniksa Pharmaceuticals, Ltd.Phase 2/Phase 3

See all Mavrilimumab clinical trials

Clinical Trial Summary for Mavrilimumab

Top disease conditions for Mavrilimumab
Top clinical trial sponsors for Mavrilimumab

See all Mavrilimumab clinical trials

US Patents for Mavrilimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mavrilimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Mavrilimumab   Start Trial Bispecific chimeric antigen receptors and methods of use thereof to treat cancer Seattle Children's Hospital (Seattle, WA)   Start Trial
Mavrilimumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Mavrilimumab   Start Trial Meditopes and meditope-binding antibodies and uses thereof City of Hope (Duarte, CA)   Start Trial
Mavrilimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Mavrilimumab

Drugname Country Document Number Estimated Expiration Related US Patent
Mavrilimumab Australia 2013220749 2032-02-15   Start Trial
Mavrilimumab Brazil 112014019627 2032-02-15   Start Trial
Mavrilimumab Canada 2862476 2032-02-15   Start Trial
Mavrilimumab China 104114705 2032-02-15   Start Trial
Mavrilimumab China 108570468 2032-02-15   Start Trial
Mavrilimumab European Patent Office 2814963 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
McKinsey
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.